

Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH

Entrala A^{1,2,3}, Loli-Ausejo D⁴, Pérez T⁵, Losantos I⁶, Cabañas R^{1,2,3,7,8}, Caballero T^{1,2,3,7}

¹Department of Allergy, Hospital Universitario La Paz, Madrid, Spain

²Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

³CSUR de Angioedema Hereditario, Hospital Universitario La Paz, Madrid, Spain

⁴Department of Allergy, Hospital Clinic de Barcelona, Universitat de Barcelona, Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

⁵Department of Pharmacy, Hospital Universitario La Paz, Madrid, Spain

⁶Department of Biostatistics, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

⁷Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain

⁸PIELenRed Consortium

J Investig Allergol Clin Immunol 2024; Vol. 34(4): 261-263
doi: 10.18176/jiaci.0977

Key words: Hereditary angioedema due to C1-inhibitor deficiency. Health-related quality of life. AEQoL. HAE-QoL. Subcutaneous plasma-derived C1-INH.

Palabras clave: Angioedema hereditario por déficit de C1 inhibidor. Calidad de vida relacionada con la salud. AEQoL. HAE-QoL. Derivado plasmático de C1 inhibidor subcutáneo.

Hereditary angioedema (HAE) due to C1-inhibitor deficiency (HAE-C1INH) is an incurable and life-threatening disease [1,2]. Angioedema attacks interfere with the patient's daily and work activities and decrease health-related quality of life (HRQOL), even during angioedema-free intervals [3].

Replacement therapy with subcutaneous (SC) plasma-derived C1-inhibitor (pdC1INH) (Berinert, CSL Behring) was shown to be effective as long-term prophylaxis (LTP) in patients with HAE-C1INH [4,5] and is currently one of the first-choice treatments for LTP in this disease [1,2]. It is easier to self-administer and more efficacious than intravenous (IV) pdC1INH [6]. It has recently become available in Spain [7,8].

The aim of our study was to assess efficacy and changes in HRQOL in HAE-C1INH patients treated with SC pdC1INH (Berinert) as LTP under real-world conditions.

We performed a retrospective, cross-sectional study (Ethics Committee approval, PI-4598). All the patients diagnosed with HAE-C1INH who had received SC pdC1INH for at least 6 months until December 2021 were included. Demographic and clinical data were collected retrospectively.

Patients prospectively completed a symptom diary, 2 HRQOL questionnaires, and a treatment satisfaction questionnaire at their follow-up visits as part of their routine health care. HRQOL was assessed using the Angioedema Quality of Life questionnaire (AE-QoL), a specific questionnaire for angioedema as a symptom, and the HAE-QoL, which is specific for HAE-C1INH [3] at 2 time points: prior to starting SC pdC1INH LTP and 6 months later. Disease activity was measured as the monthly attack rate (number of attacks/mo) during the 6 months prior to starting SC pdC1INH LTP and during the 6 months after starting this treatment. The degree of satisfaction with SC pdC1INH LTP was assessed using the specific Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4) [9] 6 months after starting the treatment. Statistical analysis was performed using IBM SPSS for Windows, Version 24.0 (IBM Corp.).

We included 8 patients (5 women [62.5%]) diagnosed with type I or II HAE-C1INH treated with SC pdC1INH LTP. Mean (SD) age was 47.1 (14.7) years and mean weight 83.1 (17.1) kg (Table S1). Six patients had previously undergone LTP (3 with attenuated androgens [AAs] and 3 with IV pdC1INH) (Table S1). The reasons for switching treatment were adverse effects of AA, the lack of effectiveness of previous LTP, and the high emotional burden of IV treatment. Two patients started LTP with SC pdC1INH because of inability to self-administer IV medication.

The protocol followed that suggested by the Spanish Group for the Study of Bradykinin-mediated Angioedema (GEAB) of the Spanish Society of Allergy and Clinical Immunology (SEAC). SC pdC1INH LTP was initiated with 2000 IU twice per week in most patients (Figure) [10].

The initial SC pdC1INH doses can be seen in Table S1. Six patients received 2000 IU twice weekly. Patient 3 started at a higher dose (4000 IU twice weekly) owing to high disease activity (prior treatment with IV pdC1INH 1000 IU every 2 days). Patient 1 started with a lower dose (1500 IU twice weekly) because the treatment was initiated in 2018, before SC pdC1INH came onto the market in Spain (the patient signed a consent form). Over the first 6 months, the SC pdC1INH dose had to be increased in 3 patients (Patients 4, 6, and 7), reduced in 4 (Patients 1, 2, 3, and 8), and maintained in Patient 5. The initial median (IQR) SC pdC1INH dose was 37.8% (35.19%-54.29%) of the corresponding dose in the summary of product characteristics (SmPC); at 6 months this was 54.9% (53.425-61.95) (Table S1). All the patients received doses lower than that indicated in the SmPC (60 IU/kg) [8] throughout the study.

The median number of attacks per month prior to SC pdC1INH LTP was 1.93 (1.53-2.94), and a nearly significant reduction was observed 6 months after initiation of SC pdC1INH LTP (median, 0.3 [0-1.69]; $P=0.069$) (Table S1 and Table S5). The clinical condition improved in 6 patients, 3 of whom, remarkably, became asymptomatic (0 attacks/mo). Only 2 patients experienced a worsening of their HAE activity 6 months after the beginning of SC pdC1INH: patient 6 achieved a reduction in attacks 3 months after the dose increase (8 months after initiation of SC pdC1INH LTP), and patient 8 did not complete the dose increase as prescribed.




Figure. Subcutaneous pdC1INH LTP protocol of the Spanish Group for the Study of Bradykinin-mediated Angioedema.

HRQOL improved 6 months after initiation of treatment according to both the AE-QoL and HAE-QoL.

The total AE-QoL score improved, and the difference was higher than the minimal clinically important difference (6 points) [3], although it was not statistically significant (Table S5). There was also a nonsignificant improvement in all the dimension scores (Table S2), except in the Fatigue/Mood domain. Individual scores are shown in Table S5.

The total HAE-QoL score also improved (nearly significant, $P=.093$) (Table S5), as did all the dimension scores, except for the Disease-related Stigma domain (Table S3). Statistical significance was achieved in 2 dimensions: Perceived Control over Illness ($P=.031$) and Mental Health ($P=.020$). Individual scores are shown in Table S5.

According to the TSQM questionnaire, the mean satisfaction rate was 77.7% (Table S4). Only 2 patients had adverse effects, mainly local discomfort at the injection site (itching and stinging).

In our series, the use of lower doses of SC pdC1INH than those approved in the SmPC and even lower than those proposed in the GEAB protocol proved to be effective, even in patients with high body weight and decreased HAE activity, increased HRQOL, and high overall satisfaction. Other authors also used SC pdC1INH as LTP at doses lower than those approved in the SmPC (42.86-65.22 IU/kg/wk) in real life, with good results [11]. The lower SC pdC1INH doses imply a reduction in direct costs and the possibility of prescribing this treatment to more patients.

In conclusion, the GEAB protocol for starting LTP with SC pdC1INH in HAE-C1INH proved useful for individualizing treatment in our case series.

Since the present study is limited by the small number of patients and the short observation period, further studies are needed.

Funding

This project was awarded a grant (first PUBLIBECA prize from CSL-Behring) at the SEAIC 2021 National Congress. The grant was to cover medical writing expenses during the preparation of the manuscript.

Conflicts of Interest

This work received the first PUBLI-Scholarship award granted by CSL-Behring at the National Congress of the Spanish Society of Allergy and Clinical Immunology in 2021.

A. Entrala has received funding to attend conferences/educational events from CSL-Behring and Novartis.

R. Cabañas has received grant research support and/or speaker/consultancy fees from Novartis and Pharming NV. She has also received funding to attend conferences/educational events from CSL-Behring, Novartis, and Takeda.

T. Caballero has received grant research support and/or speaker/consultancy fees from Astria, BioCryst, CSL-Behring, Novartis, Pharming NV, and Takeda. She has also received funding to attend conferences/educational events from BioCryst, CSL-Behring, Novartis, Pharming, and Takeda. T Caballero is/has been a clinical trial/registry investigator for BioCryst, CSL-Behring, IONIS, Novartis, Pharming NV, and Takeda. She is a researcher in the IdiPAZ research program.

Previous Presentations

These data were presented as an oral communication at the National Congress of the Spanish Society of Allergy and Clinical Immunology in 2021.

References

1. Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. *Allergy*. 2022;77:1961-90.
2. Caballero T, Leonart-Bellfill R, Pedrosa M, Ferrer L, Guilarte M. Expert Review and Consensus on the Treat-to-Target Management of Hereditary Angioedema: From Scientific Evidence to Clinical Practice. *J Investig Allergol Clin Immunol*. 2023 Jul 27;33(4):238-49. doi: 10.18176/jiaci.0875.
3. Caballero T, Prior N. Burden of Illness and Quality-of-Life Measures in Angioedema Conditions. *Immunol Allergy Clin North Am*. 2017;37:597-616.
4. Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 Inhibitor. *N Engl J Med*. 2017;376:1131-40.
5. Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, et al. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. *J Allergy Clin Immunol Pract*. 2018;6:1733-41.e3.
6. Bernstein JA, Li HH, Craig TJ, Manning ME, Lawo J-P, Machnig T, et al. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. *Allergy Asthma Clin Immunol*. 2019;15:13.
7. Caballero T. Treatment of Hereditary Angioedema. *J Investig Allergol Clin Immunol*. 2021;31:1-16.
8. Berinert® 2000, 3000 [European Union Summary of Product Characteristics]. Available at: <https://labeling.cslbehring.com/SMPC/EU/Berinert/EN/Berinert-2000-3000-SPC.pdf> Accessed on 27/02/2023
9. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. *Health Qual Life Outcomes*. 2004;2:12.
10. Protocolo del GEAB de uso de Berinert® subcutáneo como profilaxis a largo plazo. Available at: <https://www.seaic.org/wp-content/uploads/2020/08/PROTOCOLO-BERINERT-SUBCUTANEO-COMO-PLP-EN-AEH-C1-INH-GEAB-2020-08-18-FINAL.pdf>. Accessed on 27/02/2023
11. Zanichelli A, Suffritti C, Popescu Janu V, Merlo A, Cogliati C. Real-Life Experience With Subcutaneous Plasma-Derived C1-Inhibitor for Long-Term Prophylaxis in Patients With Hereditary Angioedema: A Case Series. *Front Allergy*. 2022;11;3:818741

■ *Manuscript received June 14, 2023; accepted for publication December 5, 2023.*

Ana Entrala Bueso
Department of Allergy
Hospital Universitario La Paz
Paseo de la Castellana, 261
28046 Madrid, Spain
E-mail: anaentrala@gmail.com